Bristol-Myers Squibb Glucophage XR
Executive Summary
NDA submitted for once-daily formulation of anti-diabetic metformin Nov. 12. The filing is one of two near-term Glucophage line extensions; an NDA for a metformin/glyburide combination was filed Sept. 30